Cargando…

Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study

PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) enhance angiogenesis and neurogenesis. Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) play an important role in neurogenesis and angiogenesis. However, the effect of SSRIs on cognition and serum BDNF and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Liu, Xuan, Li, Tong, Xu, Bing, Fu, Binfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721155/
https://www.ncbi.nlm.nih.gov/pubmed/35002241
http://dx.doi.org/10.2147/NDT.S334647
_version_ 1784625276219555840
author Zhang, Lei
Liu, Xuan
Li, Tong
Xu, Bing
Fu, Binfang
author_facet Zhang, Lei
Liu, Xuan
Li, Tong
Xu, Bing
Fu, Binfang
author_sort Zhang, Lei
collection PubMed
description PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) enhance angiogenesis and neurogenesis. Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) play an important role in neurogenesis and angiogenesis. However, the effect of SSRIs on cognition and serum BDNF and VEGF in patients with vascular cognitive impairment no dementia (VCIND) is largely unknown. PATIENTS AND METHODS: It was an open label study. Fifty VCIND patients were randomly allocated to receive fluoxetine (20 mg/d; n = 25) or no fluoxetine (control group; n = 25) for 12 weeks. VCIND patients received fluoxetine 20 mg/d and secondary prevention of stroke for 12 weeks in the fluoxetine group, whereas the control group received only secondary prevention of stroke for 12 weeks. The primary outcome and secondary outcome were of assessment of Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog) score, Ten Point Clock drawing test score (TPC), Verbal Fluency Test (VFT), Trail Making Test form a (TMTa), Trail Making Test form b (TMTb) and Digit Span Test score at baseline and week 12 in the both groups. And serum concentration of BDNF and VEGF was also tested at baseline and week 12 in both groups. RESULTS: After 12 weeks, TPC scores increased more significantly in the fluoxetine group than in the control group, while TMTa score and TMTb score were decreased more significantly in the fluoxetine group than in the control group. We also found that the serum concentration of BDNF and VEGF in the fluoxetine group increased more significantly than in the control group. However, we found no significant differences in mean change from baseline between fluoxetine and control group in ADAS-Cog score, Digit Span Test score and VFT score. CONCLUSION: Fluoxetine may enhance cognition in certain cognitive domains and serum concentration of BDNF and VEGF in patients with VCIND.
format Online
Article
Text
id pubmed-8721155
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87211552022-01-06 Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study Zhang, Lei Liu, Xuan Li, Tong Xu, Bing Fu, Binfang Neuropsychiatr Dis Treat Clinical Trial Report PURPOSE: Selective serotonin reuptake inhibitors (SSRIs) enhance angiogenesis and neurogenesis. Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) play an important role in neurogenesis and angiogenesis. However, the effect of SSRIs on cognition and serum BDNF and VEGF in patients with vascular cognitive impairment no dementia (VCIND) is largely unknown. PATIENTS AND METHODS: It was an open label study. Fifty VCIND patients were randomly allocated to receive fluoxetine (20 mg/d; n = 25) or no fluoxetine (control group; n = 25) for 12 weeks. VCIND patients received fluoxetine 20 mg/d and secondary prevention of stroke for 12 weeks in the fluoxetine group, whereas the control group received only secondary prevention of stroke for 12 weeks. The primary outcome and secondary outcome were of assessment of Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog) score, Ten Point Clock drawing test score (TPC), Verbal Fluency Test (VFT), Trail Making Test form a (TMTa), Trail Making Test form b (TMTb) and Digit Span Test score at baseline and week 12 in the both groups. And serum concentration of BDNF and VEGF was also tested at baseline and week 12 in both groups. RESULTS: After 12 weeks, TPC scores increased more significantly in the fluoxetine group than in the control group, while TMTa score and TMTb score were decreased more significantly in the fluoxetine group than in the control group. We also found that the serum concentration of BDNF and VEGF in the fluoxetine group increased more significantly than in the control group. However, we found no significant differences in mean change from baseline between fluoxetine and control group in ADAS-Cog score, Digit Span Test score and VFT score. CONCLUSION: Fluoxetine may enhance cognition in certain cognitive domains and serum concentration of BDNF and VEGF in patients with VCIND. Dove 2021-12-29 /pmc/articles/PMC8721155/ /pubmed/35002241 http://dx.doi.org/10.2147/NDT.S334647 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Zhang, Lei
Liu, Xuan
Li, Tong
Xu, Bing
Fu, Binfang
Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title_full Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title_fullStr Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title_full_unstemmed Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title_short Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study
title_sort fluoxetine may enhance vegf, bdnf and cognition in patients with vascular cognitive impairment no dementia: an open-label randomized clinical study
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721155/
https://www.ncbi.nlm.nih.gov/pubmed/35002241
http://dx.doi.org/10.2147/NDT.S334647
work_keys_str_mv AT zhanglei fluoxetinemayenhancevegfbdnfandcognitioninpatientswithvascularcognitiveimpairmentnodementiaanopenlabelrandomizedclinicalstudy
AT liuxuan fluoxetinemayenhancevegfbdnfandcognitioninpatientswithvascularcognitiveimpairmentnodementiaanopenlabelrandomizedclinicalstudy
AT litong fluoxetinemayenhancevegfbdnfandcognitioninpatientswithvascularcognitiveimpairmentnodementiaanopenlabelrandomizedclinicalstudy
AT xubing fluoxetinemayenhancevegfbdnfandcognitioninpatientswithvascularcognitiveimpairmentnodementiaanopenlabelrandomizedclinicalstudy
AT fubinfang fluoxetinemayenhancevegfbdnfandcognitioninpatientswithvascularcognitiveimpairmentnodementiaanopenlabelrandomizedclinicalstudy